All right, folks. Now, each January, investors wait with baiter breath for my next guest to post his 10 predictions. So, let's bring him in.Cross Mark Global, their CEO and CIO, Bob Dah. Uh, Bob, so we we got your 2025 recap as usual. It's pretty good.A lot more checks than X's. Uh, we can't go over the whole thing, but I do want to zero in on the equal weight outperforming because even though that wasn't the case for the year, recently that has been the case. >> We got that so wrong.You're absolutely right ...

OmniUltra Platform Overview - OmniUltra is the first and only transgenic chicken producing antibodies on a human framework with ultralong CDRH3s, similar to those found in cows[24] - Ultralong CDRH3s can reach binding pockets inaccessible to other antibodies, and can be cleaved to create Picobodies, the smallest functional antibody fragment[24] - OmniUltra is engineered for *in vivo* optimization, generating molecules pre-selected for function, affinity, and structural stability, potentially uncovering novel binding domains[27] - The platform leverages a transgenic chicken host to deliver biologically-optimized structured peptides, unlike phage display or other peptide discovery technologies[28] Competitive Advantages and Biological Intelligence - Antibodies generated *in vivo* are naturally optimized for specificity and developability[37] - The immune system in engineered transgenic animals creates optimized antibodies for human therapeutics, termed Biological Intelligence, increasing the efficiency and probability of success in therapeutic antibody discovery[37] - Greater evolutionary distance yields greater immunogenicity and more antibody diversity in chicken platforms[38] Epitope Coverage and Peptide Discovery - OmniUltra chickens are immunoresponsive to a variety of antigen targets[42] - Ultralong CDRH3 IgG clones bind to overlapping and novel epitopes[45] - OmniUltra can identify naturally-optimized peptide sequences that can be chemically synthesized as picobodies and retain antibody-like affinity and specificity to the immunized target[49] Market Opportunities and Expansion - The estimated total available commercial therapeutic market in 2034 is over $1 trillion, including peptides ($332 billion), bi-specifics ($460 billion), CAR-T ($224 billion), and radiopharma ($14 billion)[64] - Expansion into peptides provides an opportunity to drive service revenue and increases the potential audience of new partners by adding >130 peptide companies[66, 68]

Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS, France, December 15, 2025, 10:05 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announce ...

MENLO PARK, Calif., Dec. 15, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12 at 7:30 a.m. PT.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 day ...

PresentationJason KolbertD. Boral Capital LLC, Research Division Good. Good morning, everyone. My name is Jason Kolbert. I am the senior biotechnology analyst, really the senior health care analyst at D. Boral Capital. One of the companies that I've been following for, got to be 10, maybe even 15 years, right, Phil?, is CytoSorbents. I'm fascinated by the company in part because, believe it or not, I have a background in chromatography going back many, many years. And when Phil first introduced the concept ...

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...

Summary of Anixa Biosciences Conference Call Company Overview - **Company**: Anixa Biosciences (NasdaqCM: ANIX) - **Industry**: Biotechnology - **Focus**: Clinical stage biotech company with two early-stage clinical developments: a CAR T cell therapy for ovarian cancer and a breast cancer vaccine program [1][2] Key Points and Arguments Breast Cancer Vaccine Program - The breast cancer vaccine program is designed as both a treatment and prophylactic, focusing on a novel approach targeting a protein expressed only during lactation, which is produced by cancer cells in some breast cancer patients [6][7][8] - The phase one study presented at the 2025 San Antonio Breast Cancer Symposium showed promising results, with the data exceeding expectations and being superior to other cancer vaccines in phase one trials [9][10] Phase One Study Results - The phase one trial involved three cohorts of women: 1. Women with a history of triple-negative breast cancer at high risk of recurrence 2. Women with BRCA mutations who opted for prophylactic mastectomies 3. Women with residual disease post-treatment [10][12][13] - Key findings: - The vaccine was found to be safe with no significant side effects, only mild injection site irritation [11][18] - Strong immune responses were observed in 75% of participants [11][20] - No significant differences in immune response rates among the cohorts [21] Future Clinical Trials - Plans for a phase two study in a neoadjuvant setting, where newly diagnosed breast cancer patients will receive the vaccine alongside standard care (Keytruda) [24][25] - The trial is expected to enroll 80 to 100 women and take approximately two to three years to complete, with data available much sooner [29][31] - The goal is to demonstrate the vaccine's efficacy in reducing tumor burden before surgery, potentially leading to better outcomes and lower recurrence rates [25][27] Corporate Strategy and Partnerships - Anixa aims to establish pharmaceutical partnerships to fund further trials and commercialize the vaccine, reducing reliance on capital markets [28] - The IND has been transferred from Cleveland Clinic to Anixa, allowing the company to sponsor the trial [32] Broader Research Initiatives - Anixa is also advancing preclinical and R&D vaccine programs targeting other cancers, including ovarian, prostate, lung, and colon cancers, with a focus on identifying unique proteins associated with these cancers [34][35] Additional Important Insights - The approach of targeting unique proteins on cancer cells aims to avoid autoimmune responses, which is a significant advantage over traditional cancer vaccine strategies [7][35] - The company is optimistic about the potential for the breast cancer vaccine findings to be replicated in other cancer types, indicating a broader application of their research strategy [34][35]

For three decades, central nervous system (CNS) drug development was a tough space for investors, scarred by failed bets on Alzheimer's disease, plateauing first-generation antidepressants, and setbacks in safety and efficacy.   But advances in receptor-selective chemistry and so-called “biased agonism” – steering toward therapeutic pathways and away from areas that cause side effects – are reviving interest in the field.   Successes such as esketamine for depression or cannabinoids for epilepsy have shown ...

Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ:SNY) . The new agreement is built on the existing relationship between the two companies, following Sanofi’s acquisition earlier this year of Dren Bio’s DR-0201 program for deep B-cell depletion. • Sanofi shares are experiencing downward pressure. Why are SNY shares declining?The collaboration covers the discovery and development of a next-generation B-cell depleting therapy for the treatment of ...

Nuvation Bio Inc. (NUVB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individu ...